Country Club Bank Sells 1,487 Shares of Amgen Inc. (NASDAQ:AMGN)

Country Club Bank decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 3.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 42,919 shares of the medical research company’s stock after selling 1,487 shares during the quarter. Amgen comprises 0.9% of Country Club Bank’s portfolio, making the stock its 28th biggest holding. Country Club Bank’s holdings in Amgen were worth $13,849,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Strategic Financial Concepts LLC purchased a new position in shares of Amgen during the second quarter valued at approximately $26,000. Hershey Financial Advisers LLC purchased a new position in Amgen during the 2nd quarter valued at $30,000. nVerses Capital LLC bought a new position in Amgen in the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC purchased a new stake in Amgen in the second quarter worth $33,000. Finally, Matrix Trust Co bought a new stake in shares of Amgen during the third quarter worth $36,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.4 %

Amgen stock opened at $316.98 on Friday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The stock has a market cap of $170.04 billion, a PE ratio of 45.28, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The stock has a 50-day moving average of $325.49 and a two-hundred day moving average of $313.47. Amgen Inc. has a one year low of $249.70 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). The company had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period in the previous year, the business earned $5.00 earnings per share. On average, research analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.84%. Amgen’s payout ratio is 128.57%.

Analyst Ratings Changes

AMGN has been the topic of several recent analyst reports. Morgan Stanley reduced their price target on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $305.00 target price (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Barclays boosted their price target on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Jefferies Financial Group restated a “buy” rating and set a $380.00 price objective (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $332.55.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.